Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, aged 18 years and older~* Chronic hepatitis C genotype 1 (as specified in the protocol)~* Treatment naive~* Females who are post-menopausal and amenorrheic must have a follicle-stimulating hormone (FSH) at screening. Females of childbearing potential must have a negative pregnancy test at screening and baseline. Females must use a non-hormonal method of contraception and must agree not to get pregnant during the study and for 6 months following the discontinuation of standard of care (SOC).~* Fertile males must agree to use a condom and his female partner must agree to use 1 or more methods of contraception. Males must not donate sperm during the study and 3 months following the last exposure to RBV.~Exclusion Criteria:~* Body mass index (BMI) \>36 kilograms (kg)/square meter (m\^2)~* Pregnant or nursing females or females of childbearing potential not willing to comply with contraceptive measures per protocol. Men whose female partners are pregnant or contemplating pregnancy. - Coinfection with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV)~* Other significant diseases including liver disease~* History of drug or alcohol dependence or addiction within the past 6 months~* History of participation in a clinical trial with a protease inhibitor or previous treatment with a protease inhibitor, where at least 1 dose of the protease inhibitor was consumed.~* Use of herbal or homeopathic products, illicit drugs, cytochrome P450 (CYP) 3A4/5 substrates, inducers or inhibitors, hormonal methods of contraception, corticosteroids, immunosuppressive, or cytotoxic agents within 28 days of the first dose of study drug.~* Have a clinically significant laboratory abnormality at screening (as specified in the protocol).~* Segment 1: Participants with any history of decompensated liver disease defined as cirrhotic participants with a Child-Pugh score of \> or = to 7. Segment 2: Participants who have had a liver biopsy that shows bridging fibrosis or cirrhosis.~* Nonalcoholic steatohepatitis if ballooning degeneration or Mallory bodies are present on liver biopsy.~* Participants who prematurely discontinued, interrupted, or dose reduced prior Peg-IFN and RBV therapy due to noncompliance or safety issues.~* Encephalopathy or altered mental status of any etiology.~* History of moderate, severe, or uncontrolled psychiatric disease (as specified in the protocol).~* History of malignancy of any organ system treated or untreated within the past 5 years.~* Use of colony stimulating factor agents within 90 days prior to baseline.~* History of seizure disorder.~* History of known coagulopathy including hemophilia.~* Clinically of significant findings on fundoscopic or retinal examination at screening~* History of immunologically mediate disease.~* History of clinical evidence of chronic cardiac disease (as specified in the protocol)~* Received concomitant systemic antibiotic, antifungals, or antivirals for the treatment of active infection within 14 days prior to the first dose of the study drug (as specified in the protocol)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Segment 1: 200 milligrams (mg) ACH-0141625 (Type: EXPERIMENTAL): 200 mg ACH-0141625 for 28 days plus pegylated interferon (Peg-IFN) alpha-2a and ribavirin (RBV) for 48 weeks
- Segment 1: 400 mg ACH-0141625 (Type: EXPERIMENTAL): 400 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus RBV for 48 weeks
- Segment 1: 800 mg ACH-0141625 (Type: EXPERIMENTAL): 800 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus RBV for 48 weeks
- Segment 1: Placebo (Type: PLACEBO_COMPARATOR): Placebo for 28 days plus Peg-IFN alpha-2a plus RBV for 48 weeks
- Segment 2: 200 mg ACH-0141625 (Type: EXPERIMENTAL): 200 mg ACH-0141625 for 12 weeks plus Peg-IFN and RBV for up to a total of 24 or 48 weeks
- Segment 2 : 400 mg ACH-0141625 (Type: EXPERIMENTAL): 400 mg ACH-0141625 for 12 weeks plus Peg-IFN and RBV for up to a total of 24 or 48 weeks
- Segment 2 : 800 mg ACH-0141625 (Type: EXPERIMENTAL): 800 mg ACH-0141625 for 12 weeks plus Peg-IFN and RBV for up to a total of 24 or 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete